Skip to main content
Top navigation
  • Sustainability reports
  • Focus area: Increase resource efficiency
  • Governance
  • Please fill out this field

Main navigation

    • Our offering
        • ReciBioPharm
            • Services
                • ATMP fill and finish
                • Biologics development
                • Biologics manufacturing
            • Modalities
                • RNA therapies
                    • Plasmid manufacturing
                    • RNA manufacturing
                    • Lipid nanoparticle
                    • Continuous RNA manufacturing
                • Virotherapy manufacturing
                    • Plasmid manufacturing
                    • Cell & virus Banking
                    • Oncolytic virus production
                    • Gene therapy manufacturing
                    • Viral vector vaccine
                • Microbiome live biotherapeutics
        • Solids & others
            • New product introduction
                • Technology Transfer
                • Product development
            • Manufacturing
                • Solids
                • Semi-solids
                • Liquids
            • Pharmaceutical packaging
            • Special services
                • Controlled drugs
                • High Potent
        • Aseptic fill & finish
            • Manufacturing
                • Sterile vial filling
                • PFS and cartridges
                • Lyophilisation
                • Blow-fill-seal
                • Ampoules
            • Special services
                • Ophthalmics
                • Beta-lactams
                • Vaccine manufacturing
        • Additional services
            • ReciPredict
            • Analytical services
            • Regulatory
    • About us
        • About us
            • Our leadership
            • Why partner with us
            • Locations
        • Sustainability
            • Sustainability reports
            • Sustainability strategy
            • Net Zero commitment
            • Governance
        • News & Events
            • Press releases
            • Events
    • Resources
        • Resources
    • Careers
        • Careers
            • Who we are
            • Working with us
            • What you can do
            • Job search
Contact
Contact
Please fill out this field
No banner Image

Press releases

  • Home
  • About us
  • Press releases
  • Facebook
  • Linkedin
  • Twitter
  • Email

BU-NOT-SET

CONTACT US
May 13 2025
Recipharm and PLG announce strategic partnership to accelerate development projects
May 08 2025
NewBiologix licenses Xcell-Eng-HEK293 cell line to ReciBioPharm for development and manufacture of Adeno-Associated Virus (AAV) therapeutics
April 09 2025
Recipharm exceeds sustainability goals with major milestones
March 14 2025
Recipharm reports record 2024 revenue and strategic milestones
February 27 2025
Recipharm further expands product development capabilities with new pilot scale development
February 05 2025
Recipharm expands aseptic filling capabilities for process development, pilot scale and clinical supply
January 22 2025
Spektus Pharma and Recipharm Announce Strategic Partnership to Develop and Supply CNS Medicines Using Flexitab™ Oral Drug Delivery Platform
January 13 2025
ReciBioPharm secures a significant grant to advance RNA manufacturing
November 19 2024
Recipharm's full range Oral Solid Dosage (OSD) capabilities meet growing industry demands
October 03 2024
Recipharm strengthens pharmaceutical development capabilities with strategic investments

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • …
  • Next page
  • Last page
How we can help

Contact us to discuss your next project or learn more about our offerings.

Contact us Linkedin YouTube
Footer
  • Privacy policy
  • Cookies
  • Website terms
  • Sitemap
  • Cookie settings
  • Terms & conditions
  • Code of Conduct
© 2025

Recipharm AB. All rights reserved. RECIPHARM® is a registered trademark owned by Recipharm AB.

Delivered by Investisdigital [iDX]